# US 2019/0314412 A1 · Methods and compositions high scale therapeutic production of memory nk cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314412 A1
- Document ID: US20190314412A1
- Status: Published application
- Kind: A1
- Application number: 16/422,003
- Filed: 2019-05-24
- Published: 2019-10-17
- Earliest claimed: 2016-11-08
- Assignees: University of Central Florida Research Foundation, Inc.
- Applicants: University of Central Florida Research Foundation, Inc.
- Inventors: Alicja J. Copik; Robert Y. Igarashi; Jeremiah L. Oyer; Deborah Altomare
- Web page: https://patentgrep.com/patent/US20190314412A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 35/33: Fibroblasts
- A61K 38/20: Interleukins [IL]
- A61K 38/208: {IL-12}
- A61K 38/2086: {IL-13 to IL-16}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 2501/20: Cytokines; Chemokines
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2312: Interleukin-12 (IL-12)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2318: Interleukin-18 (IL-18)
- C12N 2501/2321: Interleukin-21 (IL-21)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are compositions and methods relating to the expansion of memory NK cells.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for increasing the number of memory NK cells comprising
a) preactivating NK cells by contacting at least one NK cell with at least one stimulatory cytokine; and
b) expanding the preactivated NK cells of step a), by contacting the preactivated NK cells with plasma membrane (PM) particles with surface bound interleukin (IL)-21 (PM21) particles, exosomes (EX) with surface bound IL-21 (EX21) exosomes, or feeder cells (FC) with surface bound IL-21 (FC21) feeder cells, or any combination thereof.

### Claim 22 (depends on 21)

The method of claim 21, further comprising maintaining the contact in (b) for at least about 15 days, wherein a 10,000 fold increase in NK cell number is achieved.

### Claim 23 (depends on 21)

The method of claim 21, further comprising a washing step after the preactivation in step (a) and/or after the expansion in step (b).

### Claim 24 (depends on 21)

The method of claim 21, wherein the NK cells are obtained from an unselected population of peripheral blood mononuclear cells, cord blood or a stem cell population.

### Claim 25 (depends on 21)

The method of claim 21, wherein preactivating the NK cells comprises contacting the NK cells with at least one stimulatory cytokine selected from the group consisting of Interleukin-12 (IL-12), Interleukin-15 (IL-15), and Interleukin-18 (IL-18).

### Claim 26 (depends on 21)

The method of claim 21, wherein preactivating the NK cells comprises contacting the NK cells with any combination of two stimulatory cytokines selected from the group consisting of IL-12, IL-15, and IL-18.

### Claim 27 (depends on 21)

The method of claim 21, wherein preactivating the NK cells comprises contacting the NK cells with IL-12, IL-15, and IL-18.

### Claim 28 (depends on 24)

The method of claim 24, further comprising contacting the NK cells with an one or more NK cell effector agents selected from the group consisting of 4-1BB ligand (4-1BBL), Interleukin-2 (IL-2), Major histocompatibility complex class I-related chain AB (MICAS), UL16 Binding Protein 2 (ULBP2), Intracellular adhesion molecule 1(ICAM-1), 2B4, /signaling lymphocyte activation molecule (SLAM) family member 2 (F2) (BCM1/SLAMF2), cluster of differentiation 155 CD155), cluster of differentiation 112 (CD112), C-C chemokine receptor type 7 (CCR7), DnaX activation protein of 12 kDa (DAP12), and DnaX activation protein of 10 kDa (DAP10), and any combination thereof.

### Claim 29 (depends on 21)

The method of claim 21, wherein preactivating the NK cells comprises contacting the NK cells with the at least one stimulatory cytokine in vitro, in vivo, or ex vivo.

### Claim 30 (depends on 21)

The method of claim 21, wherein preactivating the NK cells comprises contacting the NK cells with at least one stimulatory cytokine for a period of about 6 to about 24 hours.

### Claim 31 (depends on 21)

The method of claim 21, wherein the PM21 particles, EX21 exosomes, or FC21 feeder cells comprise one or more stimulatory peptides coupled to a membrane-inserting peptide.

### Claim 32 (depends on 31)

The method of claim 31, wherein the stimulatory peptide coupled to a membrane-inserting peptide comprises a fused peptide that is capable of membrane insertion with affinity for a lipid bilayer, wherein the fused peptide comprises a segment of IG4, CD4, or a combination thereof.

### Claim 33 (depends on 31)

The method of claim 31, wherein the one or more stimulatory peptides coupled to a membrane-inserting peptide is a fusion protein encoded by recombinant DNA.

### Claim 34 (depends on 31)

The method of claim 31, wherein the membrane-inserting peptide comprises human Fc, GPI, trans-membrane T-cell receptor, or pHLIP.

### Claim 35 (depends on 31)

The method of claim 31, wherein the one or more stimulatory peptides are selected from the group consisting of 4-1BBL, IL-2, IL-12, IL-18, IL-21, MICA/B, ULBP2, ICAM-1, 2B4,BCM1/SLAMF2, CD155, CD112, CCR7, DAP12, and DAP10.

### Claim 36 (depends on 21)

The method of claim 21, wherein the NK cells are contacted with the PM21 particles, EX21 exosomes, or FC21 feeder cells in vitro, in vivo, or ex vivo.

### Claim 37 (depends on 21)

The method of claim 21, wherein the NK cells of step (a) are contacted with PM21 particles, EX21 exosomes, or FC21 feeder cells for a period of 7 days to 60 days.

### Claim 38 (depends on 21)

The method of claim 21, further comprising resting the expanded memory NK cells following step (b).

### Claim 39 (depends on 38)

The method of claim 38, wherein the cells are memory NK cells are rested for at least 1, 2, 3, 4 or 5 days.

### Claim 40 (depends on 38)

The method of claim 38, wherein the memory NK cells are rested for no more than 5 days.

### Claim 41 (depends on 21)

The method of claim 21, wherein the PM21 particles, EX21 exosomes, or FC21 feeder cells comprise 4-1BBL and IL-21.

### Claim 42 (depends on 41)

The method of claim 41, wherein the 4-1BBL and IL-21 are coupled to a membrane-inserting peptide.

### Claim 43

An activated NK cell composition comprising NK cells following contact with at least one stimulatory cytokine selected from the group consisting of IL-12, IL-15, and IL-18 for at least about 6 hours.

### Claim 44 (depends on 43)

The cell composition of claim 43, in contact with PM21 particles, EX21 exosomes, FC21 feeder cells, or any combination thereof.

### Claim 45 (depends on 44)

The composition of claim 44, further comprising an additional one or more cytokines selected from the group consisting of 4-1BBL, IL-2, IL-21, MICA/B, ULBP2, ICAM-1, 2B4BCM1/SLAMF2, CD155, CD112, CCR7, DAP12, DAP10, and any combination thereof.

### Claim 46 (depends on 44)

The composition of claim 44, in vitro or ex vivo.

### Claim 47 (depends on 44)

The composition of claim 44, wherein the PM21 particles, EX21 exosomes, or FC21 feeder cells comprise one or more stimulatory peptides coupled to a membrane-inserting peptide.

### Claim 48 (depends on 47)

The composition of claim 47, wherein each of the one or more stimulatory peptides coupled to a membrane-inserting peptide comprises a fused peptide that is capable of membrane insertion with affinity for a lipid bilayer, wherein the fused peptide comprises a segment of IG4, CD4, or a combination thereof.

### Claim 49 (depends on 47)

The composition of claim 47, wherein the one or more stimulatory cytokines coupled to a membrane-inserting peptide is a fusion protein encoded by recombinant DNA.

### Claim 50 (depends on 47)

The composition of claim 47, wherein the membrane-inserting peptide comprises human Fc, GPI, trans-membrane T-cell receptor, or pHLIP.

### Claim 51 (depends on 47)

The composition of claim 47, maintained in contact with the PM21 particles, EX21 exosomes, FC21 feeder cells or combination thereof for a period of 7 days to 60 days.

### Claim 52 (depends on 47)

The composition of claim 47, wherein the PM21 particles, EX21 exosomes, or FC21 feeder cells comprise IL-21 and further comprise 4-1BBL.

### Claim 53 (depends on 51)

The method of claim 51, wherein the 4-1BBL and IL-21 are coupled to a membrane-inserting peptide.

### Claim 54

A kit for increasing the number of memory NK cells comprising amounts of one or more stimulatory cytokines and amounts of one or more vesicles comprising IL-21, and optionally amounts of one or more NK cell effector agents.

### Claim 55 (depends on 54)

The kit of claim 54, wherein the one or more stimulatory cytokines are selected from the group consisting of IL-12, IL-15, IL-18 and any combination thereof.

### Claim 56 (depends on 54)

The kit of claim 54, wherein the one or more vesicles comprising IL-21 are selected from a PM21 particle, an EX21 exosome, a FC21 feeder cell and any combination thereof.

### Claim 57 (depends on 54)

The kit of claim 54, wherein the one or more NK cell effector agents are selected from the group consisting of 41BBL, IL-2, IL-15, IL-21, MICA/B, ULBP2, ICAM-1, 2B4, BCM1/SLAMF2, CD155, CD112, CCR7, DAP12, DAP10 and any combination thereof.

### Claim 58 (depends on 54)

The kit of claim 54, further comprising an amount of NK cells or an NK cell line.
